AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Abcellera Biologics Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.275 conference call. My name is Cameron and I'll facilitate the audio portion of today's 00:00:04.275 -- 00:00:08.319 interactive broadcast. All lines will be muted during the presentation portion of the 00:00:08.319 -- 00:00:11.402 call with an opportunity for questions and answers at the end. 00:00:11.402 -- 00:00:15.326 If you would like to ask a question, please press star followed by one on your telephone 00:00:15.326 -- 00:00:19.390 keypad. And if you are having any issues during the call, please press star followed 00:00:19.390 -- 00:00:24.015 by zero on your telephone keypad. At this time, I would like to turn the call over to 00:00:24.015 -- 00:00:27.938 Trent Steinmark, Abcelera's Chief Legal and Compliance Officer. 00:00:27.938 -- 00:00:30.179 You may proceed. 00:00:30.676 -- 00:00:31.377 Thank you. 00:00:31.377 -- 00:00:37.083 Hello, everyone. Thank you for joining us for Abcelera's third quarter 2025 earnings 00:00:37.083 -- 00:00:41.548 call. I'm Trent Steimart, Abcelera's chief legal and compliance officer. 00:00:41.548 -- 00:00:46.934 Dr. Carl Hansen, Abcelera's president and CEO, and Andrew Booth, Abcelera's chief financial 00:00:46.934 -- 00:00:52.220 officer, are also on today's call. During this call, we anticipate making projections 00:00:52.220 -- 00:00:56.764 and forward-looking statements based on our current expectations and in accordance with 00:00:56.764 -- 00:01:02.713 the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. 00:01:02.713 -- 00:01:07.300 Our actual results could differ materially due to several factors outlined in our latest 00:01:07.300 -- 00:01:12.749 Form 10-K and subsequent Forms 10-Q and 8-Q filed with the Securities and Exchange 00:01:12.749 -- 00:01:17.336 Co...